Fourth Time's the Charm: Diving Deeper into BioCryst Pharmaceuticals (NASDAQ: BCRX)
Potential Double Profit for BioCryst via Established Treatment Method
Hey there! This is my fourth article about BioCryst Pharmaceuticals, following my 2024 piece, "BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy." In that piece, I acknowledged BioCryst's heavy dependence on ORLADEYO, its blockbuster treatment for hereditary angioedema (HAE). Today, let's take a closer look at how ORLADEYO is performing.
First off, ORLADEYO net revenue soared to a whopping $134.2 million in Q1 2025, representing a staggering 51% year-over-year increase. This contributed significantly to BioCryst's total Q1 2025 revenue of $145.5 million, which also saw a 57% year-over-year increase.
Since its launch, ORLADEYO has been the company's revenue powerhouse, with annual revenues projected to hit $580-600 million in 2025 - that's a massive growth from $123 million in 2021, representing a compound annual growth rate of 20%.
The number of paid ORLADEYO patients is also on the rise. As of Q1 2025, around 84% of patients are now on the paid drug, a significant jump from the 73.5% rate at the end of 2024. This surge can be attributed to BioCryst's savvy commercial strategy and the positive impact of initiatives like the Inflation Reduction Act on Medicare affordability.
BioCryst appears to be quite confident in ORLADEYO's future, too. The company recently raised its full-year 2025 revenue guidance for ORLADEYO to $580-600 million, signaling a robust 33-37% growth over 2024.
In a nutshell, BioCryst's heavy reliance on ORLADEYO is evident from its significant impact on the company's revenue and growth trajectory. ORLADEYO is undoubtedly a cornerstone product in BioCryst's portfolio, and its success shows no signs of slowing down anytime soon. Stay tuned for more updates on BioCryst and ORLADEYO!
In the context of BioCryst Pharmaceuticals' revenue growth and reliance on ORLADEYO, it's worth noting that this treatment is not only a key revenue generator for the company in the health-and-wellness sector, but also a significant player in the science of therapies-and-treatments for hereditary angioedema. With annual revenues projected to hit $580-600 million in 2025, ORLADEYO is proving to be a major contributor to the company's success.
